In patients with MET exon 14 skipping mutations, which act as oncogenic drivers in 3–4% of NSCLC [68], selective MET inhibitors were found to cause intracranial responses in 7 of 13 (53.8%) and 5 of 7 (71.4%) patients with measurable BrMs at baseline in the GEOMETRY mono-1 ad VISION trials, respectively [94,95]. Here, MET is linked to non-small cell lung carcinoma.